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Summary 
There is increasing interest in the use of systemic therapy before surgery for 
large but operable breast cancers. It has the theoretical advantage of giving priority to 
the eradication of micrometastatic disease. 
Studies of primary systemic therapy (PST) show that tumour regression rates 
are high and more conservative surgery is possible. The survival data look promising 
although the results of randomised trials are awaited. There is no uniform approach to 
the selection of PST. Combination chemotherapy is most frequently given and few 
researchers have used biological information from the tumour to help select therapy. 
The Edinburgh study is an in vivo model of response to PST, examining 
tumour properties such as hormone receptor concentration and grade in relation to 
response and survival. Recent developments permit the use of monoclonal antibodies 
against proliferation associated antigens such as MIB -1 in archival material. This 
study relates MIB -1 to response to primary systemic hormone and chemotherapy and 
to survival. 
Tissue was available for 65 patients treated between 1984 and 1988 and 
MIB -1 index was calculated in 61. Indices ranged from 0.01 to 0.89 and there was a 
significant (p <0.002) difference in mean MIB -1 between tumours classified as 
oestrogen receptor -rich ( >_20 fmol/mg) and oestrogen receptor -poor ( <20 finol/mg). 
MIB- i expression correlated with increasing grade. There was a significant 
(p <0.0004) difference in MIB -1 between tumours which responded to primary 
hormone therapy and those which did not, and between those which achieved a 
complete pathological response following primary chemotherapy and those which did 
not ((p <0.01). There was a significant (p <0.005) difference in survival between 
patients with high MIB -1 tumours treated with primary chemotherapy and those 
treated with second line chemotherapy after hormone failure. 
Patients with ER -rich tumours which are highly proliferating may not respond 
to primary hormone therapy. A trial of hormone therapy may jeopardize subsequent 
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Glossary 
ABC system Avidin- biotin -peroxidase complex 
AMG Aminoglutethimide 
AJCC American Joint Committee on Cancer 
Complete pathological response 
Absence of tumour on histological examination of the breast 
following PST 
CHOP cyclophosphamide lgm/m2, vincristine 1.4mg/m2, adriamycin 
50mg/m2, prednisolone 40 mg daily for five days 
DAB Diaminobenzidine Identifies the site of an antibody by staining 
brown when incubated with peroxidase 
DCC Dextran coated charcoal assay to measure oestrogen 
receptor activity in fmol receptor sites /mg protein 
Dose intensity Amount of drug administered per unit time expressed 
as mg/m2 /week 
Downstaging The use of chemotherapy or hormone therapy to reduce primary 
tumour size or abolish oedema or erythema, altering tumour 
staging 
Early breast cancer Traditionally operable, T1/T2 with minimal node involvement 
Not a pure clinical or biologically sound term 
EBCTCG Early breast cancer trialist's collaborative group including 
representatives from 61 institutes 
EORTC European Organisation for Research and Treatment of Cancer 
ER Oestrogen receptor. Oestrogen binding protein MW 65,000, 
found in 50 -60% of all breast cancers 
FCS Foetal calf serum 
Growth fraction Fraction of proliferating cells in a tumour 
High risk operable disease 
Stage I or II with heavy nodal involvement ± high grade 
LABC Locally advanced breast cancer. Equivalent to Stage 3 
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LHRH 
(UICC AJCC 1983), which includes 3a (operable) T3NO and Nl, 
3b and T4 (inoperable). Includes inflammatory carcinoma - an 
aggressive subgroup of LABC with diffuse oedema and 
erythema frequently without a palpable mass 
Luteinising hormone releasing hormone. A decapeptide 
released from the hypothalamus which stimulates release of 
luteinising hormone from the pituitary 
Mitotic figure index Number of mitoses per 1000 tumour cells 
NHL Non Hodgkins lymphoma 
NSABP National Surgical Adjuvant Breast and Bowel Project 
Proliferation associated antigens 
Antigens which are detectable on growing or dividing cells ie in 
G1,G2,M and S phase 
PST Primary systemic (neoadjuvant) therapy 
Recombinant Different parts of genes combined together and re- introduced 
into the cell where it is reproduced along with the cells own 
genes 
SPF S -phase fraction 




Tris buffered saline 
Union Internationale Contra Cancer In 1985, together with 
AJCC agreed to a world wide TNM staging system 
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Proliferative activity, measured by MIB -1, and outcome in primary breast cancer 
following systemic therapy. 
The concept of primary systemic therapy [PST] in breast cancer is not new 
and the ideas behind it have developed over the last century. Since Beatsonl challenged 
the theory of parasitic infestation of the breast, hormone manipulation in advanced and 
metastatic breast cancer has played a major palliative role. In 1952 Schoenbach2 
demonstrated the value of chemotherapy in metastatic breast cancer using aminopterin, a 
folic acid antagonist with proven success in childhood leukaemia. In non -metastatic 
breast cancer, radical surgery often carried out as an emergency remained accepted 
surgical practice long after Haagenson3 described the factors associated with 
inoperability. However the natural history of the disease suggests that in most patients 
surgical removal of the primary tumour is not curative. 
The hypothesis that micrometastatic disease at presentation was 
responsible for treatment failure was confirmed experimentally by Schabel,4 who showed 
in mice that chemotherapy given after excision of a C3H mammary tumour could prevent 
metastatic growth and be curative. Around the same time Fisher,5 Bonadonna 6 and 
Nissen -Meyer, pioneered the use of adjuvant chemotherapy. These trials, plus many 
more, have recently been subject to metanalysis 8 which has revealed an improved 
survival for all patient groups at ten years. It is now clear that the natural history of 
operable breast cancer is altered by early chemotherapy or hormone therapy. 
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Interest then focused on systemic therapy for local disease with a high 
tumour burden. Stage 3 (UICC) disease9 is associated with a five year survival rate of 
20% 10-12 De Lena 13 was the first to question the mere supporting role of 
chemotherapy; he treated patients with inoperable Stage 3 disease with primary 
adriamycin and vincristine followed by radiotherapy. Tumour regression was achieved in 
89 %, dispelling anxiety about the chemosensitivity of large tumours with possible small 
growth fractions. Local control was ultimately accomplished with adjuvant radiotherapy 
in 97% of patients with non -inflammatory disease and a comparison with historical 
controls suggested improved survival at five years. 
Numerous non -randomised studies of PST followed,14-17 confirming high 
rates of tumour regression, often complete, achievable with combination chemotherapy. 
Downstaging rendered many "inoperable" tumours operable and allowed more 
conservative surgery. The effect of PST on survival is unknown, but five, ten and 15 year 
disease free survival figures of 53 %,18 17 %19 and 28%20 respectively, are encouraging 
and randomised prospective studies are in progress. 
Studies of PST regularly included T3 NO or N1 tumours, classified as 
Stage 3 because of their size, not their inoperability, and because primary tumour size is 
related to micrometastatic burden PST in high risk operable disease became a logical 
step. 21'22 The first UK study of PST for large operable breast cancers was in Edinburgh 
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from 1984 - 1990 23 and the survival data are currently being analysed. In addition to 
the downstaging effect, the monitoring of primary tumour behaviour provided a unique in 
vivo model of response by which to examine tumour properties before and after therapy. 
Also, residual disease was surgically excised, permitting pre- and post -treatment 
properties to be related to immediate regression. 
In the Edinburgh study, choice of PST was based on the patient's 
menopausal and tumour oestrogen receptor status. Other studies have concentrated on 
chemotherapy alone and the contribution of hormones has received little attention. Early 
results from the Edinburgh study were encouraging and a randomised trial of pre- versus 
post- operative chemotherapy or hormone therapy was started in 1990.24 Several other 
trials of similar design are in progress 25,26 and the NSABP B -1 8 - "one of the most 
biologically compelling in the 30 year history of the NSABP".27 
What systemic therapy should be selected? It is useful to examine the 
rationale for treatment choice both in metastatic disease and in adjuvant therapy. In 
metastatic disease, ER positivity of the primary tumour is a potent predictor of hormone 
induced response, associated with objective regression or useful palliation in 50% of 
patients.28 In the adjuvant setting however, the picture is less clear. From the EBCTCG 
overview, all patients treated with tamoxifen showed an advantage in terms of risk of 
relapse or death, irrespective of receptor status, implying that ER negative 
micrometastatic disease may not be completely hormone refractory. The therapeutic 
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index may be improved by chemoendocrine therapy as results from the adjuvant NSABP 
B -1629 and the EORTC study of LABC 30 suggest but these results conflict with 
theoretical arguments to support combined treatment.31 The case for combined 
treatment is based on tumour heterogeneity and that against on the unfavourable effect of 
hormones on actively cycling cells. Accumulation of cells in non -proliferative phases of 
the cell cycle, as seen in vitro following LHRH agonists 32 and tamoxifen33'34 and in 
vivo following tamoxifen,35 may lessen the effect of chemotherapy. 
Consequently it is not known whether ER positive tumours or a subset of 
these, would be better treated with chemotherapy initially or in combination with 
hormone therapy or whether some ER negative tumours should receive hormone therapy 
in addition to chemotherapy. 
In selecting PST, it is important to decide which tumours should be 
treated and with what. Combinations of treatment and optimum dose should be 
considered. LABC is not uniformly fatal and up to 17% of patients have been recorded 
as surviving 20 years following surgery or radiotherapy.12 These should be identified to 
prevent over -treatment. The value of a tumour model is that ineffective treatment may be 
identified quickly. In the Edinburgh 23 study a trial of hormone therapy was initiated but 
chemotherapy was substituted if the tumour did not regress. 
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Powles36 found no overall difference in survival in a group of patients 
with metastatic disease treated with chemotherapy compared to untreated historical 
controls. More recently, correlations between dose intensity and response37 rate of 
response and improved survival38 and improved disease -free survival at two years 
following dose intensification - albeit when compared with historical controls39 have been 
reported. This suggests that a subset of patients with metastatic disease may survive 
longer after high dose chemotherapy but care must be taken in extrapolating the results 
from metastatic to primary disease. The impact of high dose primary systemic 
chemotherapy is being examined in LABC with some promising early results.4o 
The choice of treatment for ER positive tumours is more difficult. The 
treatment of LABC in elderly patients with Tamoxifen is accepted practice. Regression is 
slow but it is unknown whether overall survival is any worse than if chemotherapy had 
been given. There is no clinical or pathological equivalent to ER for predicting 
chemotherapy response. Poorly differentiated and high grade tumours have been reported 
to show higher response rates to chemotherapy;83 cellular proliferation, which has been 
valuable in improving treatment in experimental tumours, may have predictive value. 
The Edinburgh large tumour study provides an opportunity to study the 
significance of cellular proliferation in vivo, in relation to both immediate response and to 
long term clinical behaviour. If tumour response is to have validity as an endpoint, it must 
be shown to correlate with overall survival. Although remission does not predict for 
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survival, data from PST studies suggests a correlation between rate of response and 
survival. 
41'42 
Camplejohn43 specifies criteria for a measure of proliferation in oncology. 
First it should have clinical value in different cancers. Second it should be technically 
simple to measure and neither too time consuming nor expensive. 
The most widely used technique is S -phase fraction [SPF] using flow 
cytometric analysis which is strongly associated in most studies with clinical outcome of 
early breast cancer. High SPF generally -47 but not unanimously 8 correlates with 
poorer disease free and overall survival. It has been argued that SPF is a surrogate 
measure of grade but it is increasingly being reported as an independent prognostic 
factor.49 
-5o It can be applied to fresh and paraffin- embedded tissue, and has been shown 
to identify patients retrospectively who benefited from combination chemotherapy as an 
adjuvant51'52 and as treatment for metastatic disease.53 Also in several small studies, 
regression following neo- adjuvant treatment correlates with SPF.54 -57 
Flow cytometry, however, is not technically simple. SPF cannot be 
calculated in up to 25% of samples43'48 because of background debris or limitations in 
mathematical modelling in multiploid tumours. Its prognostic value depends on the 
simplistic division into "low" or "high". 58 
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Proliferation -associated antigens can now be identified using monoclonal 
antibodies. Ki -67 antibody is widely used to recognise a non -histone nuclear protein 
which is expressed on all proliferating cells which are in the active parts of the cell cycle 
i.e. G1, S, G2 and mitosis but which is absent in Go cells.59 Ki -67 status has been shown 
to correlate with grade in NHL60 and breast cancer. 61 -64 Associations between Ki -67 
staining and recurrence,65 surviva1,66 response of metastases to chemotherapy68 and 
response to endocrine therapy67 have all been reported. Fresh tissue is required because 
the technique is unreliable using paraffin-embedded material. 
Recently a method based on high temperature microwave heating of tissue 
sections has been described to retrieve antigens from formalin fixed paraffin- embedded 
tissues.69 This unmasks the antigen, making it available for immunohistochemical staining 
and has increased the range of monoclonal antibodies which can be used to study archival 
material. Ki -S I is one such antibody which detects a proliferation antigen. Ki -Si status 
has been shown to have independent prognostic value71'72 but the antibody is not 
commercially available. MIB -1 is a mutine antibody recently raised against recombinant 
parts of the Ki -67 antigen73 which can be tested on routinely processed paraffin 
embedded tissue, using the antigen retrieval microwave method. It shows an identical 
staining pattern to Ki -67 on fresh material and correlates well with Ki -67 in paraffin 
embedded sections of NHL74 and breast.75'76 MIB -1 also correlates with SPF 77 mitotic 
figure index 84 and inversely with ER.68 The technique appears to be a highly 
9 
reproducible indicator of cell proliferation in breast cancer and provides an opportunity to 
study growth fractions by simple immunostaining. MIB -1 has also been found to be an 
important predictor of surviva1,78 and to correlate indirectly with chemotherapy induced 
response in high grade sarcomas.79 In addition to these promising findings, it is relatively 
inexpensive. 
The present study investidgates MIB- 1 staining in primary tumours from 
patients in a PST study which has the longest UK follow up data. MIB -1 values were 
ralated to patients survival and the relation between pre-treatment MIB -1 staining and 
tumour regression following hormone and chemotherapy was examined. 
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Patient population. 
Patients and methods: 
93 patients received either primary hormone therapy or chemotherapy within 
the Edinburgh large tumour study between July 1984 and August 1988.23'24 A pre- 
treatment wedge biopsy or node biopsy was obtained for histological and biochemical 
examination at presentation. 66 of the original paraffin blocks were available from the 
archives of the Department of Pathology, University of Edinburgh, for M B -1 
immunohistochemical staining. Tumours had been originally fixed in buffered 
formaldehyde solution. 
Systemic therapy was given for three months, after which a mastectomy or 
wide local excision was carried out. Pre -menopausal patients were treated by 
surgical oophorectomy or with LHRH analogue goserelin (Zoladex ICI 118630; 
3.6mg subcutaneous depot preparation at 28 day intervals), and post -menopausal 
patients either with tamoxifen (20mg daily), aminoglutethimide (1000mg plus 40mg 
prednisolone daily) or 4 hydroxyandrostenedione (4 -0HA Ciba Geigy CGP 32349; 
250mg intramuscularly at 14 day intervals). Between 1984 - 1986 primary hormone 
therapy was prescribed irrespective of ER status but from 1987 it was reserved for 
patients with ER rich ( >_ 20 fmol/mg cytosol protein) tumours. If tumour 
progression occurred following hormone therapy, treatment was stopped and 
chemotherapy with CHOP started cyclophosphamide lgm/m2, vincristine 1.4mg/m2, 
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adriamycin 50mg/m2 and prednisolone 40mg daily for five days) for four cycles at 
three weekly intervals. Patients with ER negative tumours or those with ER values< 
20 finol/mg were treated immediately with CHOP. 
Tumour response was based on weekly tumour measurements by the author 
(PL) or her successor (Dr E Anderson). Three categories of response were defined. 
"Significant regression" and "significant progression" were defined as a 95% 
probability that the regression line of tumour volumes against time deviated from the 
horizontal. Response was classified as "no change" where the regression slope did not 
achieve this significance. The development of lymphoedema constituted progression. 
Survival data was obtained by PL from patients' records and was available for 
all 66 patients. 
Preparation of slides 
New 4 pm sections from the original pretreatment paraffin blocks were cut 
unto poly -L- lysine slides. Tissue was processed for immunohistochemistry using the 
microwave antigen retrieval technique,69 and immunostaining carried out according 
to the avidin - biotin (ABC) technique70 with modifications by Cattoretti.80 
Microwave processing. 
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Sections were de -waxed in xylene, rehydrated through a series of graded 
alcohols to 95% and incubated in 1% hydrogen peroxide for 30 minutes to block any 
endogenous breast tissue peroxidase. After washing, the slides were submerged in a 
solution of 0.01M Citric acid (pH 6.0) and microwaved for three periods of five 
minutes at maximum power in a 750 W microwave oven. Sections were washed in 
0.05m Tris buffered saline (TB S) for five minutes and covered in 20% fetal calf 
serum (FCS) in TBS for ten minutes. 
Immunohistochemistry. 
Sections were then covered with MIB -1 antibody ( Immunotech., Marseille), 
diluted 1:50 in TBS/FCS for 30 minutes at room temperature and washed twice 
(x five min.) with TBS. Slides were covered with biotinylated rabbit anti -mouse 
antibody (1:100 dilution) for 20 minutes at room temperature, washed and covered 
with avidin biotin peroxidase complex (Dako Strept ABComplex, Denmark) for 20 
minutes. Finally slides were soaked in a 1 mg/ml solution of diaminobenzidine (DAB) 
containing 5% hydrogen peroxidase, washed and lightly counterstained with 
haematoxylin. 
Quantitation of MIS -1 staining 
Representative fields from the most strongly stained areas of tumour were selected in 
collaboration with a Consultant Pathologist (Dr M. McIntyre, Western General 
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Hospital, Edinburgh). Using a 10 x 10 grid, at least 1000 tumour cells were counted 
at 400x magnification. MIB -1 antigen positive cells were identified by DAB brown 
staining, contrasting clearly with blue haematoxylin stained MIB -1 negative tumour 
cells and an index was calculated.81 
MIB -1 index = number of MIB -1 positive cells 
total number of tumour cells. 
Statistical analysis. 
Because grading is discontinuous, descriptive statistics are expressed as 
mode, median and range. 
Survival was calculated using the method of Kaplan and Meier which allows 
for the use of censored data. Curves were drawn using an MS DOS computer 




The median patient age was 53 (range 38 -69). Three were pathological 
grade 1, 15 grade 2, 33 grade 3 and ten were not graded. Clinical and pathological 
details are in Table 1. The distribution of ER status is in Fig 1 and was skewed with 
modal, median and mean values of 0, 36 and 83 finol/mg respectively. 
Immunohistochemical staining. 
A MIB -1 index was calculated in 61 of 66 sections. In three cases, no 
tumour was identified in the block and in two there were insufficient tumour cells to 
calculate an index. Stain was present in both non -malignant and malignant cells. Non 
malignant proliferating cells found in the centre of germinal follicles showed strong 
nuclear staining (Fig 2a). MIB -1 staining of malignant cells demonstrated 2 patterns: 
1. strong staining of nuclei, often in a particulate pattern as if identifying 
nucleoli. 
2. at mitosis, chromosomal staining was very strong but diffuse cytoplasmic 
staining (Fig 2b) was also seen. 
The percentage of cells which stained was very variable (1 -89 %). In some 
tumours less than 1% of malignant cells stained and these tumours often but not 
invariably were well differentiated and demonstrated gland formation (Fig 3b). In 
others most malignant cells were positive with a range of staining both in intensity and 
percentage of nucleus stained (Fig 3c). The distribution of MIB -1 (Fig 4) was 
approximately normal with mean and median values of 0.37 and 0.34 respectively. In 
order to examine the relation of ATM- 1 to other tumour properties, indices <0.4 
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were referred to as "low" and >0.4 as "high ". There was no correlation between MIB- 
1 and ER (Fig 5) when both were assessed as continuous variables. However when 
ER values were divided into <_20 or >20 fmol/mg (the criterion for clinical decision 
making) there was a significant difference (p < 0.002) in MIB -1 values between ER- 
rich and poor (Fig 5b). MIB -1 values >0.6 were only seen in ER -poor tumours, 
although approximately 25% of ER -rich tumours had MIB -1 values greater than 
average. 
MIB -1 and grade. 
59 of the 66 tumours had been graded previously by a pathologist (Dr 
Patterson, Department of Pathology, University of Edinburgh) as part of the large 
tumour study. MIB -1 expression was associated with increasing grade. The relation of 
grade(1 -3) to MIB -1 was examined using the Mann -Whitney U test (Fig 6) and was 
significant between grade 1 and 2 (p < 0.002) and between grade 2 and 3 (p < 0.05). 
Survival 
There was no significant difference in survival between ER -poor (<_20 
finol/mg) and ER -rich ( >20 finol/mg) tumours (Fig 7) or low MIB -1 ( <0.4) and high 
MIB -1 ( >_0.4) tumours (Fig 8). Survival of patients treated with hormone therapy or 
chemotherapy alone was similar, the median survival not yet having been reached. The 
median survival of patients treated with chemotherapy after hormone failure was only 
4.3 years. 
16 
Response to primary hormone therapy. 
1. Primary tumour response. 
The details of patients treated with hormone therapy are in Tables 2a 
and 2b. Those who responded to therapy are in Table 3 and those who progressed in 
Table 4. Mean MIB -1 values for responders and non responders are in Fig 9. A 
Mann -Whitney U test showed a significant (P < 0.004) difference in MIB -1 values 
between tumours which responded to treatment within 3 months and those which 
either failed to respond or progressed. 25/35 of ER -rich tumours had low MIB -1 
values and 17 of these responded to primary hormone therapy (68 %), and 10/34 ER- 
rich tumours had high MIB -1 values, of which 5/10 responded. No tumour with a 
MIB -1 value >0.5 responded to hormone therapy. 
2. Survival. 
As seen in Fig 10 the survival of patients treated with hormones alone 
was not significantly different from the survival of patients treated with primary 
chemotherapy. There was no difference in the survival of patients treated with 
hormones alone with respect to MIB -1 status (Fig 11). Nine of the 35 ER -rich 
patients had MIB -1 values >0.4. The behaviour of this group of ER -rich high 
proliferation tumours was compared to that of ER-rich low proliferation disease. 
The median survival of ER -rich high MIB -1 tumours was shorter than that of ER -rich 
low MIB -1 tumours (5 years v 9 years). 
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3. Relation of primary tumour response to survival. 
Tumours which did not respond to primary hormone therapy and were 
treated with second line chemotherapy had a poorer prognosis. This difference was 
most evident for ER -rich tumours with high MIB -1 values. The median survival of 
this group of high proliferation rate tumours was only 3 years (Fig 12). Numbers are 
small and the difference is not significant but failure to respond to hormone therapy 
even when subsequent chemotherapy is given may be associated with a poor outcome. 
Chemotherapy 
1. Primary tumour response. 
The details of patients treated with first line chemotherapy are in Table 
5a. Five of these patients achieved a complete pathological response (Table 5b). A 
Mann -Whitney U test of the MIB -1 values of those achieving complete pathological 
response compared with those who did not was significant at a level of p < 0.01 (Fig 
13). 
The details of patients treated with chemotherapy after hormone failure are in 
Table 6 and the details of those who achieved regression and those who did not are 
shown in Tables 6a and 6b respectively. Only 1/17 patients achieved a complete 
pathological response. No change in tumour size was found in 6/17. 
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2. Survival. 
Survival following chemotherapy (primary or secondary) was similar 
for high and low MIB -1 disease (Fig 14). Patients treated with primary rather than 
secondary chemotherapy appear to have an improved long term survival (Fig 15) but 
the difference is not statistically significant. 
. When patients treated with primary chemotherapy only were examined 
those with the highest values had the longest survival but numbers were small and not 
statistically significance (Fig 16). However when patients with high MIB -1 levels 
were studied there was a significant difference in survival (p < 0.005) between 
patients treated with primary chemotherapy or with chemotherapy after hormone 
failure (Fig 17). Patients with high MIB -1 levels treated with primary chemotherapy 
had not yet reached their median survival and those who received hormone therapy 




The patients studied here were all treated within the first Edinburgh study of 
pre -operative systemic therapy for large operable tumours. They are therefore a 
selected group with considerable local disease and no clinically overt metastases, who 
are nonetheless likely to have micrometastatic disease. The ER distribution however 
was similar to that of an unselected group of patients presenting to the Edinburgh 
Breast Surgical Clinic:82 the distribution was skew with a modal value of 0 fiuol/mg, 
most of the very high ( >100 finol/mg) ER values occurred in post -menopausal 
patients and ER status increased with age. 
The long term outcome of treatment was favourable - 50% of patients 
surviving ten years. This compares with a historical 10 year survival rate of less than 
20% and rates of 31% and 17% in two of the most mature PST studies.19'20 There 
was no difference in outcome between ER -poor and ER -rich tumours and 60% of 
patients with ER -poor disease were alive at 10 years. Neither was there any overall 
difference in outcome between patients treated with hormones alone and those 
treated with first line chemotherapy. As first line treatment with chemotherapy was 
based on ER negativity of the tumour, itself a poor prognostic factor in patients not 
receiving systemic therapy, it might be expected that this group would fare badly. In 
fact the median survival of ER -poor patients treated with primary chemotherapy and 
ER -rich patients treated successfully with hormone therapy has not yet been reached. 
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MIB-1 
Tumours blocks were up to 11 years old and numerous sections had been 
taken previously, which may explain why no residual tumour was identified in 3 
cases. It was relatively easy to distinguish positive brown DAB staining from blue 
haematoxylin staining although there was a range of staining intensity from weakly 
positive to strongly positive nucleii as has been previously noted.78 Inflammatory 
infiltrates were not uncommon and co- operation with a pathologist was important to 
verify the denominator. The distribution of 1VlTB -1 indices in the large tumours 
studied was approximately normal. The median (0.34) and mean (0.37) MIB -1 
indices are higher than that those previously reported (0.25, 0.28) in a study which 
employed automated analysis to measure the percentage of total nuclear area 
staining.78 The range of positivity (1 -89 %) is similar to that (0 -80 %) reported with 
the Ki -67 proliferation antibody.65 
1VIIB -1 correlated with grade, a finding also previously reported78 and one 
which is not unexpected as mitotic index is one component of grade. MIB -1 did not, 
as has been previously suggested,68 correlate inversely with ER when both MIB -1 
and ER were considered as continuous variables.This lack of correlation applied if 
the ER -poor and ER -rich tumours were considered separately. However the mean 
MIB -1 of ER -poor tumours was statistically significantly higher than that of ER -rich 
tumours. Increased MIB -1 expression, an indicator of tumour growth fraction, might 
be expected in ER -poor tumours but approximately 25% of ER -rich tumours also 
expressed greater than average MIB -1 levels. 
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MIB -1 alone was not predictive of long term survival, an association which 
has been previously demonstrated in patients with operable breast cancer who have 
received no systemic therapy.78 Such associations have been regularly reported 
between survival and other measures of proliferation such as SPF and Ki -67. It is 
likely that any predictive value was negated by systemic therapy. 
MI3-1 and response to hormones 
No ER -poor tumour responded to hormone therapy and in the latter part of 
the study hormone therapy was only given as PST in patients with ER values >20 
finol/mg. ER values <_ 20 fmol/mg therefore predicted for failure of primary tumour 
response. Values >20 finol/mg did not guarantee response and although overall mean 
MIB -1 values were significantly higher in non responders than in responders (Fig 9) 
three tumours which progressed had higher than average ER and MIB -1 values 
(Table 7). 
Patients with ER -rich high MIB -1 disease had a shorter survival. Four of the 
nine patients failed to respond to hormone therapy and all died within five years 
despite treatment with second line chemotherapy. 
It is not possible to say whether the poorer outcome was due inherently to 
more aggressive disease or to the effects of treatment. These tumours may have been 
resistant to CHOP or the treatment sequence may have affected response. Tumours 
which failed to respond to one hormone therapy were treated with chemotherapy and 
alternative hormone therapy was not tried. It is unknown whether these tumours 
would fail to respond to all hormone therapies. There was (Fig 17) a statistically 
significant difference in survival between first and second line chemotherapy and this 
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was most evident in high MIB -1 disease (Fig 12). The chance of a mutation 
conferring drug resistance increases with each doubling therefore large tumours at 
presentation would be expected to contain such resistant clones already. In certain 
highly proliferating tumours any delay in effective treatment may jeopardize cell kill. 
Besides this time factor, hormone treatment may, in some rapidly proliferating 
tumours promote G1 accumulation32 -35 and limit cell kill from subsequent cell cycle 
specific chemotherapeutic agents. It is unknown how long any such hormone induced 
effect may last. 
MIB -1 and response to chemotherapy 
Some large cancers, clinically localised to the breast, had high proliferation 
indices. Immediate treatment with combination chemotherapy, avoiding the delay 
caused by major surgery, resulted in a 50% ten year survival rate. Patients with the 
highest MIB -1 values of all fared the best although the numbers are as yet small. 
Patients who achieved a complete pathological response had significantly higher 
MIB -1 values than those who did not, and similar associations between response and 
pre- treatment proliferation have been reported for SPF54 
-57 and Ki -67.68 As seen 
above, patients with high MIB -1 values survived for a significantly shorter time if a 
trial of hormone therapy was given first. 
In conclusion: 
1. ER -poor disease predicted for failure of response to primary hormone therapy and 
patients unsuitable for primary hormone therapy could be selected on the basis of 
conventional tumour properties. 
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2. As in metastatic disease ER values >20 fmol /mg did not always predict for primary 
tumour response. Approximately 50% of ER -rich tumours progressed on therapy 
and some of these had ER values >200fmol/mg (Fig 18). Most ER -rich tumours had 
lower than average MIB -1 value. Approximately 25% in this study had above 
average values and tumours with values MM-1 values >0.5 did not respond to 
hormone therapy. 
3. MIB -1 index alone did not predict for hormone failure. However in a subset of 
patients with ER -rich tumours and high MIB -1 values unsuccessful hormone therapy 
predicted for a significantly poorer outcome. Long term survival was compromised 
by an ineffective course of hormone treatment in patients with MIB -1 values >0.4. A 
trial of first line chemotherapy may be more appropriate. It is possible that earlier 
detection of failure to respond may allow chemotherapy to be started sooner but at 
present there are no way of detecting either early response or failure. 
4. MIB -1 as a measure of proliferation may satisfy several of Camplejohrl's 6riteria 
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of usefulness for a immunohistochemical method. It works on conventionally fixed 
material. Although there is a graduation of staining intensity, positivity can be fairly 
easily identified. Furthermore it may have a useful role in identifying patients with 
ER -rich disease who should be considered for primary chemotherapy. 
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Tables 
The tables 1 -6 summarise the clinical and biochemical data of the 61 patients studied. 
The abbreviations used are shown here. 
Di Surgery: date of diagnostic surgery (wedge biopsy or node excision) 
Ri 1: first treatment. 
1 = tamoxifen 
2 = Aminoglutethimide 
3 = LHRH 
4 = Oophorectomy 
5=4OHA 
6=CHOP 
Resp 1: first response 
health: 
1 = complete pathological response 
2 = complete clinical response 
3 = significant regression 
4 = no change 
5 = significant disease 
1 = alive and well 
2 = alive with local recurrence 
3 = alive with distant recurrence 
4 = dead from breast cancer 
5 = dead from treatment related effects 
6 = unrelated death 
ER: oestrogen receptor concentration (fmol/mg protein) 
MIB1: MIB -1 index. 
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health ER MIB -1 grade 
1 61 90985 1 3 161292 5 62 0.48 3 
2 44 291287 6 4 91294 1 6 0.8 3 
3 47 30387 3 4 6 4 101094 3 30 0.02 1 
4 59 180786 3 4 150990 4 73 0.4 ng 
5 60 181286 3 5 6 3 111089 4 259 0.58 3 
6 54 100387 5 5 6 4 230489 4 24 0.28 3 
7 63 151087 5 3 130495 2 142 0.18 ng 
9 63 240287 5 4 10691 4 225 0.07 2 
10 57 40386 2 3 51293 4 381 0.18 3 
11 61 140984 3 3 10595 3 158 0.16 2 
13 53 120588 6 4 120894 1 17 0.41 2 
14 48 250387 3 5 6 2 110789 4 0 0.71 3 
15 61 250785 2 4 140994 1 167 0.16 3 
16 53 190488 5r 5 6 4 241094 3 149 0.3 2 
17 66 300186 2 3 130694 1 147 0.29 3' 
18 49 40888 6 4 281194 1 8 0.52 3 
19 45 30485 4 4 241094 1' 93 0.17 3 
20 65 250984 1 3 221193 4 221 0.25 3 
21 52 10486 3 4 6 4 51188 4 2 0.2 3 
22 43 10786 3 3 90790 4 70 0.33 ng 
23 48 120886 3 3 51294 1 88 0.16 ng 
24 41 130585 4 3 291189 4 50 0.4 2 
25 60 40485 1 2 51286 4 45 0.04,ng 
26 41 200887 6 2 230689 4 5 0.55 ng 
28 50 11087 6 3 170894 4 15 0.01 2 
29 59 270487 5 3 20994 1 344 0.36 3 
30 54 90487 5 5 6 4 160489 4 266 0.47 2 
31 46 150586 3 3 90990 4 36 0.23 2 
32 51 190588 6 1 250794 1 8 0.82 3 
33 52 80586 3 5 6 3 90589 4 320 0.51 3 
34 42 230585 6 1 301194 1 0 0.67 2 
35 65 81184 2 3 170394 1 148 0.41 ng 
36 57 190985 2 5 6 1 170194 1 6 0.39 3 
37 60 60685 1 5 6 3 10187 4 3 0.61 3 
38 44 230186 1 5 6 2 140789 4 44 0.34 2 
39 44 170387 3 3 51289 4 23 0.32 2 
40 51 181087 6 3 140689 4 3 0.24 3 
41 58 121285 6 11087 4 0 0.26 2 
42 61 20485 6 3 190894 2 0 0.37 3 
Table 1. Clinical and pathological details of patients in whom MIB -1 
was measured. , 
no age Dx 
surgery____ 
Rx1 respl Rx2 resp2 last 
seen 
health ER mibl grade 
43 65 50785 1 5 70794 1 4 0.67 3 
44 51 250735 2 5 6 3 300195 1 3 0.63 3 
45 41 150588 6 3, 280294 1 0 0.37 3 
46 53 110785 2 3 201294 3 174 0.28 3 
47 60 50686 3 5 6 3 51194 1 53 0.26 2 
48 67 80288 5 3 241093 4 221 0.02 1 
49 53 130287 6 2 270395 1 0 0.53 3 
50 53 120588 6 3 100294 1 4 0.67 3 
51 39 120588 3 3 40894 1 46 0.2 2 
52 38 160485 4 5 6 4 10487 4 6 0.68 3 
53 55 70285 2 5 6 3 221294 1 0 0.28 3 
54 48 170985 6 1 0 120288 6 0 0.6 3 
55 53 40987 6 1 0 140294 1 0 0.89 3 
56 63 151087 6 1 0 240394 1 3 0.43 3 
57 44 300686 3 3 71194 1 30 0.45 ng 
58 45 210385 6 4 0 251285 4 0 0.09 3 
59 64 111084 1 3 70395 1 380 0.42 ng 
60 58 230188 6 3 90594 1 19 0.37 3 
61 47 250486 3 5 6 3 180494 1 13 0.05 2 
63 53 5 3 240593 1 51 0.11 1 
64 62 160888 5 3 50994 1 286 0.10 3 
65 69 240784 2 4 11194 1 55 0.31 3 
66 60 260488 5 4 6 3 70593 4 81 0.55 ng 
Table 1. Clinical and pathological details of patients in whom MIB -1 
was measured. 
27 
no age Dx 
su e _.. 
Rx1 Resp1 





last seen health ER M113-1 grade 
__. 
1 61 90985 1 3 161292 5 62 0.48 3 
20 65 250984 1 3 221193 4 221 0.25 3 
25 60 40485 1 2 51286 4 45 0.04 ng 
37 60 60685 1 5 6 3 10187 4 3 0.61 3 
38 44 230186 1 5 6 2 140789 4 44 0.34 2 
43 65 50785 1 5 70794 1 4 0.67 3 
. 59 64 111084 1 3 70395 1 380 0.42 ng 
patients treated with tamoxifen median 45 0.45 
10 57 40386 2 3 51293 4 381 0.18 3 
15 61 250785 2 4 140994 1 167 0.16 3 
17 66 300186 2 3 130694 1 147 0.29 3 
35 65 81184 2 3 170394 1 148 0.41 ng 
36 57 190985 2 5 6 1 170194 1 6 0.39 3 
44 51 250735 2 5 6 3 300195 1 3 0.63 3 
46 53 110785 2 3 201294 3 174 0.28 3 
53 55 70285 2 5 6 3 221294 1 0 0.28 3 
65 69 240784 2 4 11194 1 55 0.31 3 
patients treated with AMG median 147 0.25 
3 47 30387 3 4 6 4 101094 3 30 0.02 1 
4 59 180786 3 4 150990 4 73 0.4 ng 
5 60 181286 3 5 6 3 111089 4 259 0.58 3 
11 61 140984 3 3 10595 3 158 0.16 2 
14 48 250387 3 5 6 2 110789 4 0 0.71 3 
21 52 10486 3 4 6 4 51188 4 2 0.2 3 
22 43 10786 3 3 90790 4 70 0.33 ng 
23 48 120886 3 3 51294 1 88 0.16 ng 
31 46 150586 3 3 90990 4 36 0.23 2 
33 52 80586 3 5 6 3 90589 4 320 0.51 3 
39 44 170387 3 3 51289 4 23 0.32 2 
47 60 50686 3 5 6 3 51194 1 53 0.26 2 
51 39 120588 3 3 40894 1 46 0.2 2 
57 44 300686 3 3 71194 1 30 0.45 ng 
61 47 250486 3 5 6 3 180494 1 13 0.05 2 
Patients treated with LHRH riìern 43 0.2 
Table 2a. MI13-1 and ER in patients treated with primary hormone therapy - 
Tamoxifen, AMG or LHRH analogue. 
2A 
no age Dx 
surgery 
Rx1 Resp1 Rx2 Resp 
2 
last seen health ER M18-1 grade 
19 45 30485 4 4 241094 1 93 0.17 3 
24 41 130585 4 3 291189 4 50 0.4 2 
52 38 160485 4 5 6 4 10487 4 6 0.68 3 
patients treated by oophorectomy 
no age Dx 
su rg_ Rx1 Resp1 Rx2 Resp 2 last seen health ER MI8-1 grade 
54 100387 5 5 6 
- 
4 230489 4 24 0.28 3 
7 63 151087 5 3 130495 2 142 0.18 ng 
9 63 240287 5 4 10691 4 225 0.07 2 
16 53 190488 5 5 6 4 241094 3 149 0.3 2 
29 59 270487 5 3 20994 1 344 0.36 3 
30 54 90487 5 5 6 4 160489 4 266 0.47 2 
48 67 80288 5 3 241093 4 221 0.02 1 
63 53 5 3 240593 1 51 0.11 1 
64 62 160888 5 3 50994 1 286 0.10 3 
60_ 260488 5 4 6 3 70593 4 81 0.55 ng 
patients treated with 4OHA median 148 0.24 
Table 2b. MIB -1 and ER in patients treated with primary hormone therapy - 
oophorectomy or 4OHA. 
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no age Dx surgery Rx1 resp1 last seen health ER mibl grade 
1 61 90985 1 3 161292 5 62 0.48 3 
20 65 250984 1 3 221193 4 221 0.25 3 
25 60 40485 1 2 51286 4 45 0.04 ng 
59 64 111084 1 3 70395 1 380 0.42 ng 
10 57 40386 2 3 51293 4 381 0.18 3 
17 66 300186 2 3 130694 1 147 0.29 3 
35 65 81184 2 3 170394 1 148 0.41 ng 
46 53 110785 2 3 201294 3 174 0.28 3 
11 61 140984 3 3 10595 3 158 0.16 2 
22 43 10786 3 3 90790 4 70 0.33 ng 
23 48 120886 3 3 51294 1 88 0.16 ng 
31 46 150586 3 3 90990 4 36 0.23 2 
39 44 170387 3 3 51289 4 23 0.32 2 
51 39 120588 3 3 40894 1 46 0.2 2 
57 44 300686 3 3 71194 1 30 0.45 ng 
24 41 130585 4 3 291189 4 50 0.4 2 
7 63 151087 5 3 130495 2 142 0.18 ng 
29 59 270487 5 3 20994 1 344 0.36 3 
48 67 80288 5 3 241093 4 221 0.02 1 
63 53 5 3 240593 1 51 0.11 1 
64 62 160888 5 3 50994 1 286 0.10 3 
median 142 0.26 
Table 3. MIB -1 and ER in tumours which responded to primary hormone 
therapy. 
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health ER MIB -1 grade 
14 48 250387 3 5 6 2 110789 4 0 0.71 3 
53 55 70285 2 5 6 3 221294 1 0 0.28 3 
37 60 60685 1 5 6 3 10187 4 3 0.61 3 
44 51 250735 2 5 6 3 300195 1 3 0.63 3 
43 65 50785 1 5 70794 1 4 0.67 3 
36 57 190985 2 5 6 1 170194 1 6 0.39 3 
52 38 160485 4 5 6 4 10487 4 6 0.68 3 
61 47 250486 3 5 6 3 180494 1 13 0.05 2 
6 54 100387 5 5 6 4 230489 4 24 0.28 3 
38 44 230186 1 5 6 2 140789 4 44 0.34 2 
47 60 50686 3 5 6 3 51194 1 53 0.26 2 
16 53 190488 5 5 6 4 241094 3 149 0.29 2 
5 60 181286 3 5 6 3 111089 4 259 0.58 3 
30 54 90487 5 5 6 4 160489 4 266 0.47 2 
33 52_ 80586_ 3 5 6 3 90589_ 4 320 0.51 3 
median ER = 13 
median MIB -1 = 0.45 
Table 4. MIB-1 and ER in tumours which progressed following hormone 
therapy. 
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no age Dx surgery Rx1 resp1 last seen health ER MIB- 
1 
grade 
2 44 291287 6 4 91294 1 6 0.8 3 
13 53 120588 6 4 120894 1 17 0.41 2 
18 49 40888 6 4 281194 1 8 0.52 3 
26 41 200887 6 2 230689 4 5 0.55 ng 
28 50 11087 6 3 170894 4 15 0.01 2 
32 51 190588 6 1 250794 1 8 0.82 3 
34 42 230585 6 1 301194 1 0 0.67 2 
40 51 181087 6 3 140689 4 3 0.24 3 
41 58 121285 6 4 11087 4 0 0.26 2 
42 61 20485 6 3 190894 2 0 0.37 3 
45 41 150588 6 3 280294 1 0 0.37 3 
49 53 130287 6 2 270395 1 0 0.53 3 
50 53 120588 6 3 100294 1 4 0.67 3 
54 48 170985 6 1 120288 6 0 0.6 3 
55 53 40987 6 1 140294 1 0 0.89 3 
56 63 151087 6 1 240394 1 3 0.43 3 
58 45 210385 6 4 251285 4 0 0.09 3 
60 58 230188 6 3 90594 1 19 0.37 3 
median 3 
a. patients treated with first line chemotherapy 
0.48 
no age Dx surgery Rx1 resp1 last seen health ER MIB - 
1 
grade 
32 51 190588 6 1 250794 1 8 0.82 3 
34 42 230585 6 1 301194 1 0 0.67 2 
54 48 170985 6 1 120288 6 0 0.6 3 
55 53 40987 6 1 140294 1 0 0.89 3 
56 63 151087 6 1 240394 1 3 0.43 3 
median 0.68 
b. Patients treated with first line chemotherapy who achieved a complete 
pathological response 
Table 5. MIB-1 and ER in a. patients treated with first line chemotherapy 
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3 37 60' 6Y: 1 5' 61 3 
44 51 250735 2 e 6 3 300195. 
11 3 0.63 3 
47 60 50686 3 5 6 3 51194 1 53 0.26 2 
53 55 70285 2 5 6 3 221294 1 0 0.28 3 
61 47 250486 3 5 6 3 180494 1 13 0.05 2 
66 60 260488 5 4 6 3 70593 4 81 0.55og 
a. tumour response following chemotherapy. median 81 0.42 






last seen health ER MIB- 
1 
grade 
3 47 30387 3 4 6 4 101094 3 30 0.02 1 
6 54 100387 5 5 6 4 230489 4 24 0.28 3 
16 53 190488 5 5 6 4 241094 3 149 0.3 2 
21 52 10486 3 4 6 4 51188 4 2 0.2 3 
30 54 90487 5 5 6 4 160489 4 266 0.47 
52 38 160485 4 5 6 4 10487 4 6 0.68 3 
b. no tumour response after chemotherapy median 27 0.32 
Table 6. MIB-1 and ER in patients treated with 2nd line chemotherapy (i.e. after 
hormone failure). 
a. tumour response after chemotherapy 
b. no tumour response after chemotherapy. 
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MIB -1 <0.4 MIB -1 >0.4 TOTAL 
ER + 0.26,0.28,0.29, 0.47,0.51,0.58 
0.34 7 
(4) (3) 
ER - 0.05,0.28,0.39 0.61,0.63,0.67, 
0.68, 0.71 8 
(3) (5) 
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Table 7. MIB -1 values of patients treated with hormone therapy 
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mean = 83 
Fig 1. The distribution of ER in all patients studied. 
Fig 2. Immunostaining of microwave processed paraffin sections of 
a. normal lymph node follicle 
b. mitotic figure showing nuclear and cytoplasmic staining 
a. Normal proliferating germinal centre cells stain strongly. 
b. M1B -1 staining at mitosis 
36 
Fig 3 Immunostaining of microwave processed paraffin sections with MIB -1 
staining . 
a. invasive ductal carcinoma - control 
b. invasive ductal carcinoma low MIB -1 staining 
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M1E3-1 index 
n = 61 
median = 0.34 
mean = 0.37 



















Pearsons correlation coefficient = -0.27 
p >0.2 not significant 






















ER <20 finol/mg ER ? 20finol/mg 
mean MIB -1 ± 95% confidence limits of mean 
0.48 ± 0.08 0.25 ± 0.05 
p = < 0.002 Mann -Whitney 
















mean ± 95% confidence intervals of mean. 
0.04 ±0.1 0.27 ±0.09 0.46 ±0.08 
p <0.002 p <0.05 
Mann -Whitney U test 





2 4 6 8 10 
time - years 
median survival ER- not yet reached 
median survival ER+ 7.7 years 
Fig 7. Survival in ER - (<20 fmol/mg) and ER+ ( >20 fmol/mg) disease. 
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time - years 
y = cumulative % surviving. 
median survival low MIB -1 
median survival high MIB -1 
9.6 years 
not yet reached 











hormone -induced progression 
regression 
mean MIB -1 ± 95% confidence limits of mean 
0.26 ± 0.06 0.45 ± 0.13 
p < 0.004 ( Mann -Whitney U test ). 
Fig 9. MIB -1 values in relation to primary tumour response 













u III I 
II 
I II 










2 4 6 0 10 
time - years 
y = cumulative % surviving 
median survival following: hormone therapy not yet reached 
1st line chemotherapy not yet reached 
2nd line chemotherapy 4.3 years 
Fig 10. Survival of patients treated with hormone therapy alone, primary 
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Fig 12. Patients treated with second line chemotherapy (after hormone 


















or no change 
mean ± 95% confidence limits 
0.68 ±0.16 0.42 ±0.21 
p < 0.01 Mann- Whitney 
Fig 13. MIB -1 values in patients treated with primary chemotherapy 
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time - years 
Fig 14. Survival following chemotherapy (primary or after hormone 






second -line cherno 
2 4 6 8 
time - years 
p=0.12 
median survival after primary chemotherapy not yet reached 
median survival after 2nd line chemotherapy 4.3 years 
Fig 15. Survival in patients treated with either primary chemotherapy 








2 time - years 6 8 
y = cumulative % surviving 
p =0.23 log rank 
median survival in high MIB -1 disease = not yet reached 
median survival in low MIB -1 disease = 7 years 
Fie l6_ Survival following primary chemotherapy in low (114) and high 
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